High-sensitivity C-reactive protein as a prognostic marker in patients undergoing valve surgery

High‑sensitivity troponin T as a prognostic marker in patients undergoing aortic valve replacement.

C-reactive protein as a prognostic marker in lymphocytic myocarditis.

The prognosis of patients with lymphocytic myocarditis (LM) is poor with the combined endpoint of death or transplant in the Myocarditis Treatment trial being 56% at 5 years. Physicians often have difficulty determining the prognosis in an individual patient. Patients with LM may have ongoing myocardial inflammation. We evaluated the ability of a serum marker of inflammation to predict prognosi...

changes of high sensitivity c-reactive protein during clopidogrel therapy in patients undergoing percutaneous coronary intervention

conclusions we found that the use of clopidogrel in patients undergoing pci had favorable effects on the suppression of hs-crp. this effect appears to be heightened and more apparent in some group of patients with co-morbidities such as diabetes and hypertension. results six hundred-fifty patients including 386 (59.4%) male and 264 (40.6%) female subjects were enrolled in the study. the mean hs...

High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus.

C-reactive protein (CRP) is a liver-derived pattern recognition molecule that is increased in inflammatory states. It rapidly increases within hours after tissue injury, and it is suggested that it is part of the innate immune system and contributes to host defense. Since cardiovascular disease is at least in part an inflammatory process, CRP has been investigated in the context of arterioscler...

High sensitivity C reactive protein as a prognostic marker in patients with mild to moderate aortic valve stenosis during lipid-lowering treatment: an SEAS substudy

AIMS To assess the prognostic importance of high-sensitive C reactive protein (hsCRP) in patients with mild to moderate aortic valve stenosis during placebo or simvastatin/ezetimibe treatment in Simvastatin and Ezetimibe in Aortic Stenosis (SEAS). METHODS AND RESULTS In 1620 SEAS patients, we measured lipids and hsCRP at baseline and after 1 year of treatment and registered during 4 years of ...